Drug intelligence / Profile preview

BPM-CA-001

Development stage: Preclinical
Lead developer: Baiya Phytopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BPM-CA-001 is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, currently under development by Baiya Phytopharm. As a checkpoint inhibitor, it is designed to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring the anti-tumor activity of T cells. The drug is produced using Baiya's proprietary plant-based expression platform (BaiyaPhyto®), which utilizes tobacco plants for the rapid and scalable production of recombinant proteins. BPM-CA-001 is currently in the IND-enabling stage of development for undisclosed indications, likely within the field of oncology given its mechanism of action.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BPM-CA-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM-CA-001.

Explore the full profile